

Disclosures

Personal Commercial (10)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|-----------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------|--------------------------------------------------|
| <i>Self</i> | | | |
| Amgen Inc. | Research/Research Grants † LDL-ALERT | Significant (>= \$5,000) | Prevention |
| Bayer | Research/Research Grants † CKD-ALERT | Significant (>= \$5,000) | Prevention |
| BMS | Research/Research Grants † HIPRO Trial, CORONA-VTE Network | Significant (>= \$5,000) | Vascular Medicine |
| BSC | Research/Research Grants † HI-PEITHO Trial, Pulmonary Vascular Imaging Study | Significant (>= \$5,000) | Pulmonary Hypertension and Venous Thromboembolic |
| ESPERION | Research/Research Grants † PAD-ALERT | Significant (>= \$5,000) | Prevention |
| Janssen Pharmaceuticals, Inc | Research/Research Grants † PREVENT-HD | Significant (>= \$5,000) | Vascular Medicine |
| NAMSA | Data Safety Monitoring Board | Modest (< \$5,000) | Vascular Medicine |
| Pfizer | Consultant Fees/Honoraria | Modest (< \$5,000) | Vascular Medicine |
| Regeneron | Research/Research Grants † ROXI-CATH | Significant (>= \$5,000) | Vascular Medicine |
| <i>Spouse/Domestic Partner/Immediate Household Member</i> | | | |
| BSC- GI/ENDOSCOPY | Salary | Significant (>= \$5,000) | Other |

Additional Personal Commercial Disclosures for Education Activities (1)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|------------------------------|-----------------------|--------------------------|--------------------------------------------------|
| <i>Self</i> | | | |
| Brigham and Women's Hospital | Salary | Significant (>= \$5,000) | Pulmonary Hypertension and Venous Thromboembolic |

Personal Organizational or Other Non-Commercial (2)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|----------------------------|---------------------------|--------------------|-------------------------------------|
| <i>Self</i> | | | |
| Penumbra | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |
| Thrombolex | Consultant Fees/Honoraria | Modest (< \$5,000) | Invasive CV Angio and Interventions |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 2/21/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 2/21/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 2/21/2026

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 7/20/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.